TY - JOUR
T1 - Cancer incidence in people with hepatitis B or C infection
T2 - a large community-based linkage study
AU - Amin, Janaki
AU - Dore, Gregory J.
AU - O'Connell, Dianne L.
AU - Bartlett, Mark
AU - Tracey, Elizabeth
AU - Kaldor, John M.
AU - Law, Matthew G.
PY - 2006/8
Y1 - 2006/8
N2 - Background/Aims: Risks of hepatocellular carcinoma (HCC) following hepatitis B and/or hepatitis C virus (HBV/HCV) infection are well known, those for other cancers are less well understood. The aim was to quantify the risk of cancers among persons diagnosed with HBV/HCV infections. Methods: The data from a cohort of 39109 HBV, 75834 HCV, and 2604 HBV/HCV co-infected persons notified to the State health department, 1990-2002, were probabilistically linked to the Cancer Registry and standardised incidence ratios (SIRs) for cancer were calculated. Results: The match rate for any cancer was 2.7%, 2.3% and 3.3% for HBV, HCV and HBV/HCV co-infected notifications. SIRs for HCC were 30.6 (95% CI 25.7-36.5), 22.7 (95% CI 19.1-26.5) and 30.3 (95% CI 13.6-67.5), respectively. Increased risk was detected for Burkitt's lymphoma and HBV (SIR 12.9, 95% CI 5.4-30.9) and immunoproliferative malignancies following HCV (SIR 5.6, 95% CI 1.8-17.5). Conclusions: The risk of HCC in the infected cohort was 20-30 times greater than in the uninfected population with SIRs two to three times greater than those for the other HBV/HCV infection associated cancers. The modest though significant risk of immunoproliferative malignancies associated with HCV infection is consistent with recent findings.
AB - Background/Aims: Risks of hepatocellular carcinoma (HCC) following hepatitis B and/or hepatitis C virus (HBV/HCV) infection are well known, those for other cancers are less well understood. The aim was to quantify the risk of cancers among persons diagnosed with HBV/HCV infections. Methods: The data from a cohort of 39109 HBV, 75834 HCV, and 2604 HBV/HCV co-infected persons notified to the State health department, 1990-2002, were probabilistically linked to the Cancer Registry and standardised incidence ratios (SIRs) for cancer were calculated. Results: The match rate for any cancer was 2.7%, 2.3% and 3.3% for HBV, HCV and HBV/HCV co-infected notifications. SIRs for HCC were 30.6 (95% CI 25.7-36.5), 22.7 (95% CI 19.1-26.5) and 30.3 (95% CI 13.6-67.5), respectively. Increased risk was detected for Burkitt's lymphoma and HBV (SIR 12.9, 95% CI 5.4-30.9) and immunoproliferative malignancies following HCV (SIR 5.6, 95% CI 1.8-17.5). Conclusions: The risk of HCC in the infected cohort was 20-30 times greater than in the uninfected population with SIRs two to three times greater than those for the other HBV/HCV infection associated cancers. The modest though significant risk of immunoproliferative malignancies associated with HCV infection is consistent with recent findings.
KW - Cancer
KW - Epidemiology
KW - Hepatitis B
KW - Hepatitis C
KW - Hepatocellular carcinoma
KW - Linkage
UR - http://www.scopus.com/inward/record.url?scp=33745699346&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2006.02.014
DO - 10.1016/j.jhep.2006.02.014
M3 - Article
C2 - 16684579
AN - SCOPUS:33745699346
SN - 0168-8278
VL - 45
SP - 197
EP - 203
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 2
ER -